Education
About Us
Working with TipRanks
Follow Us
Orchestra BioMed Holdings (OBIO)
NASDAQ:OBIO
OBIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.37 - $6.50
Previous CloseN/A
Volume15.92K
Average Volume (3M)385.32K
Market Cap
$147.84M
Enterprise Value$85.32M
Total Cash (Recent Filing)$33.92M
Total Debt (Recent Filing)$1.97M
Price to Earnings (P/E)―
Beta2.19
Next Earnings
Nov 18, 2025EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding53,955,086
10 Day Avg. Volume315,725
30 Day Avg. Volume385,325
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue28.98
Enterprise Value/Gross Profit31.28
Enterprise Value/Ebitda-1.20
Forecast
1Y Price Target
$10.00Price Target Upside264.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Regulatory ApprovalThe FDA has granted Breakthrough Device designation for atrioventricular interval modulation (AVIM) therapy, validating the novelty of the AVIM technology and the unmet medical need.
Strategic PartnershipsOrchestra BioMed announced new strategic partnerships with Ligand Pharmaceuticals and Medtronic, indicating potential growth opportunities.
Bears Say
Financial PerformanceThe company's recent dilutive equity financing while maintaining its pace of spending reduces future profitability.
Operational ChallengesThere is less confidence in the company's ability to hit R&D timelines and maintain commercial partnerships at a reasonable pace of spending.
Orchestra BioMed Holdings News
OBIO FAQ
What was Orchestra BioMed Holdings’s price range in the past 12 months?
Orchestra BioMed Holdings lowest stock price was $2.37 and its highest was $6.50 in the past 12 months.
What is Orchestra BioMed Holdings’s market cap?
Orchestra BioMed Holdings’s market cap is $147.84M.
When is Orchestra BioMed Holdings’s upcoming earnings report date?
Orchestra BioMed Holdings’s upcoming earnings report date is Nov 18, 2025 which is in 73 days.
How were Orchestra BioMed Holdings’s earnings last quarter?
Orchestra BioMed Holdings released its earnings results on Aug 12, 2025. The company reported -$0.5 earnings per share for the quarter, the consensus estimate of -$0.5 by $0.
Is Orchestra BioMed Holdings overvalued?
According to Wall Street analysts Orchestra BioMed Holdings’s price is currently Undervalued.
Does Orchestra BioMed Holdings pay dividends?
Orchestra BioMed Holdings does not currently pay dividends.
What is Orchestra BioMed Holdings’s EPS estimate?
Orchestra BioMed Holdings’s EPS estimate is -0.45.
How many shares outstanding does Orchestra BioMed Holdings have?
Orchestra BioMed Holdings has 53,955,086 shares outstanding.
What happened to Orchestra BioMed Holdings’s price movement after its last earnings report?
Orchestra BioMed Holdings reported an EPS of -$0.5 in its last earnings report, expectations of -$0.5. Following the earnings report the stock price went up 7.937%.
Which hedge fund is a major shareholder of Orchestra BioMed Holdings?
Currently, no hedge funds are holding shares in OBIO
Orchestra BioMed Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (264.96% Upside)
$10.00 (264.96% Upside)
Blogger Sentiment
Neutral
OBIO Sentiment 50%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.22%
12-Months-Change
Fundamentals
Return on Equity
-313.82%
Trailing 12-Months
Asset Growth
-40.84%
Trailing 12-Months
Company Description
Orchestra BioMed Holdings
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
OBIO Stock 12 Month Forecast
Average Price Target
$10.00
▲(264.96% Upside)
Technical Analysis
Nektar Therapeutics
―
Aldeyra Therapeutics
―
Larimar Therapeutics
―
Kodiak Sciences
―
RAPT Therapeutics
―
Ownership Overview
30.53% Insiders
4.78% Mutual Funds
25.32% Other Institutional Investors
37.24% Public Companies and
Individual Investors